A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

NCT06977880 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: LY4292009
DRUG: Placebo

Sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)